It is made available under a CC-BY-NC-ND 4.0 International license .

Longitudinal Monitoring of Glioblastoma Small Extracellular Vesicle Evolution Using a Nanodiagnostic to Detect Emergence of Glioma Stem Cells Driving Recurrent Disease

Zhen Zhang^{1,‡}, Richard J Lobb^{1,‡,*}, Paul Tooney^{2,3,4}, Jing Wang^{1,5}, Rebecca Lane¹, Quan Zhou¹, Xueming Niu¹, Sam Faulkner^{2,3}, Bryan W Day^{6,7,8}, Simon Puttick⁹, Stephen Rose⁹, Mike Fay^{3,10,11}, Matt Trau^{1,12}*

¹Centre for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia

²School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia

³Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, Newcastle, NSW 2308, Australia

⁴Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia

⁵Key Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzho*u 350007, China.

⁶Cancer Research Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, QLD 4006, Australia.

⁷School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.

⁸School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.

⁹AdvanCell Isotopes Pty Ltd, Queensland Centre for Advanced Technologies, Brisbane, QLD 4069, Australia

¹⁰School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia

¹¹GenesisCare, Lake Macquarie Private Hospital, Newcastle, NSW 2290, Australia

It is made available under a CC-BY-NC-ND 4.0 International license .

¹²School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD4072, Australia

[‡] These authors contributed equally to this work.

* Corresponding authors: Richard Lobb: richard.lobb@uq.edu.au; Matt Trau m.trau@uq.edu.au

It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Assessing therapeutic response in glioblastoma (GBM) is a major factor limiting the clinical development of new and effective therapies. The intracranial location limits serial biopsies, and only provides an intermittent view of the tumor molecular profile from the initial resection. Liquid biopsy techniques, specifically small extracellular vesicle (sEV) analysis, have the potential to overcome these limitations by providing a window into the brain using peripheral blood. To address the need for monitoring tumor evolution and therapeutic resistance, we developed a GBM biomarker panel (ATP1B2, EAAT2, CD24, CD44, CD133 and EGFR) for multiplexed profiling of sEVs using an advanced GBM Extracellular vesicle Monitoring Phenotypic Analyzer Chip (GEMPAC). We successfully tracked patient response to treatment by monitoring changes in glioma stem cell markers on circulating sEVs. We propose that these results provide a strong rationale for using GBM sEVs as a serial monitoring tool in the future clinical management of GBM patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

1 INTRODUCTION

2 Glioblastoma (GBM) is an aggressive and invasive primary brain tumor originating in the central nervous system (CNS).[1-4] The prognosis of GBM is very poor, with a median survival time of 3 approximately 14 months.[5] The rapid development of treatment resistance and frequent local 4 recurrence are key features contributing to poor patient outcomes. [1, 2, 4] Accurate monitoring of 5 GBM tumor progression is difficult and expensive; depending on imaging modalities, such as 6 magnetic resonance imaging (MRI).[6] The standard diagnostic methods in GBM management 7 (i.e. histopathology of the resection specimens) provide a limited temporal molecular profile of the 8 9 tumor and are unable to monitor tumor progression dynamically.[7] In addition, detecting early signs of tumor progression is challenging when using MRI, as the interpretation of diagnostic 10 results may be complicated by pseudo-progression after diagnosis (in the first three months after 11 radiotherapy), and by radiation necrosis (3-12 months after radiotherapy).[8, 9] Therefore, 12 developing non-invasive methods for monitoring of tumor evolution during therapy is essential to 13 navigating treatment management in this aggressive disease. 14

In recent years, liquid biopsy has emerged as a diagnostic concept that characterizes and monitors 15 tumor signatures in patient blood for tumor subtyping, prognosis monitoring, and assessing 16 treatment response.[10, 11] These non-invasive approaches can provide a view of the molecular 17 landscape of tumors from blood samples.[12] As a liquid biopsy marker, exosomes or small 18 extracellular vesicles (sEVs) are nano-sized vesicles (50-150 nm) released from cells.[7, 13, 14] 19 These vesicles are critical mediators of cell-cell communication and carry molecular cargo, 20 including proteins, nucleic acids, metabolites, and lipids.[7, 13] Most critically, several studies 21 have indicated that sEVs released by GBM tumors can cross the intact blood-brain barrier (BBB) 22 and gain access to the peripheral blood.[15-18] Several studies have reported an overall increase 23 in bulk sEV concentration in GBM patients relative to healthy controls, with sEV load apparently 24 decreasing following successful treatment of the primary tumor. [7, 15, 19, 20] Other studies, 25 26 however, have suggested that systemic increases in bulk sEV concentration are not a GBMspecific phenomenon, meaning sEV concentration alone is unlikely to be a useful metric. [21, 22] 27 Further work has demonstrated that sEVs may reflect the molecular profile of the GBM primary 28 tumor and provide clinical information to direct treatment in a timely manner[23], thereby 29 30 providing an opportunity to utilize GBM sEVs as a tool to inform clinical management decisions.

It is made available under a CC-BY-NC-ND 4.0 International license .

Progress in utilizing GBM sEVs has been limited by the challenge of specifically isolating and 31 characterizing GBM sEVs from non-target bulk sEVs in blood. Previous work has attempted to 32 identify specific protein cargo associated with circulating GBM sEVs, including transmembrane 33 L1 cell adhesion molecule, [24] epidermal growth factor receptor variant III (EGFRVIII) [23], von 34 Willebrand factor [20] and syndecan-1.[25] However, these biomarkers are also expressed in a 35 variety of normal tissues and are unable to specifically isolate GBM sEVs.[24, 26, 27] To address 36 the lack of specificity for interrogating sEVs derived from GBM tissue, we identified a unique 37 GBM signature on sEVs in blood. By integrating a GBM sEV signature with a nanoshearing 38 multiplex surface-enhanced Raman spectroscopy (SERS) platform, termed GBM EV Monitoring 39 Phenotypic Analyzer Chip (GEMPAC), we have developed the capability to sensitively profiling 40 the surface protein composition of sEVs in GBM patients with high precision. 41

In the study, the GEMPAC assay precisely captures GBM sEVs by targeting our unique CNS 42 signature composed of transmembrane proteins sodium/potassium-transporting ATPase subunit 43 beta-2 (ATP1B2) and excitatory amino acid transporter 2 (EAAT2), both of which are highly 44 expressed in both normal CNS and GBM tissue.[28-30] The malignant phenotype of captured CNS 45 sEVs were profiled by measuring glioma stem cell (GSC) markers to detect the emergence of GSC 46 subpopulations that could potentially drive recurrent disease and therapy resistance.[31] Previous 47 single-cell RNA sequencing data has revealed certain surface markers that characterize cell-likes 48 states of GSCs. In particular, CD24 expression is enriched in neural progenitor cell-like (NPC-49 50 like) cells, CD44 in mesenchymal cell-like (MES-like) cells, CD133 in oligodendrocyteprogenitor cell-like (OPC-like) cells, and EGFR in astrocyte-like (AC-like) cells. [32, 33] Using 51 our GEMPAC platform we captured GBM sEVs and monitored GSC subpopulation evolution in 52 patients before and during therapy. Encouragingly, by analyzing GSC subpopulation evolution 53 during therapy, we detected treatment response and tumor progression, thereby opening a new 54 window to facilitate clinical management of GBM. We believe that our diagnostic platform has 55 the potential to facilitate future therapies through monitoring circulating GBM GSC-related sEVs 56 to improve clinical decision-making and therefore patient survival. 57

58

It is made available under a CC-BY-NC-ND 4.0 International license .

59 **RESULTS**

60 GEMPAC chip dynamically monitors GBM sEV profiles

To accurately monitor GBM progression, we hypothesized that circulating sEVs derived from the 61 blood of GBM patients carry specific protein profiles that indicate the degree of tumor burden/or 62 progression in the CNS (Figure 1A). Specifically, we designed a panel of six surface proteins 63 capable of capturing CNS-derived sEVs and monitoring GBM by detecting GSC biomarker 64 65 expression (Figure 1B). We synthesized unique SERS nanotags conjugated with antibodies targeting GSC surface proteins and dedicated Raman molecule reporters on gold nanoparticles 66 67 bearing distinct SERS signatures indicating GSC protein expression (Supplementary, Figure S1). The sum of GSC protein expression was defined as the GEMPAC score and used to evaluate 68 disease progression (Figure 1C). Using this multiplexed approach, we combined these biomarkers 69 and investigated their capability as a dynamic monitoring tool of GBM in the blood, including 70 71 monitoring therapy response and detecting tumor progression for improved clinical management (Figure 1C). 72



73

Fig. 1. Multiplexed detection of GBM sEVs by the GEMPAC. (A) GBM tumor cells release
 sEVs into the bloodstream. GBM sEVs cross the BBB into the peripheral circulation. (B) GBM

It is made available under a CC-BY-NC-ND 4.0 International license .

sEVs are purified from blood and enriched using GEMPAC functionalized with CNS capture 76 antibodies for selective capture of CNS sEVs. The GEMPAC platform utilizes an alternating 77 current electro-hydrodynamically (AC-EHD)-induced nanoshearing strategy to minimize 78 nonspecific interactions[34] and improve specific capture of CNS sEVs. After that, SERS nanotags 79 that are conjugated with Raman reporters and detection antibodies are applied to the system for 80 multiplex readout. The SERS nanotags with special Raman molecules include, 5,5'-dithiobis (2-81 nitrobenzoic) (DTNB) (red), 4-Mercaptobenzoic acid (MBA) (blue), 4-mercaptopyridine (MPY) 82 (yellow) and 2,3,5,6-tetrafluoro-MBA (TFMBA) (green). (C) (i) Representative MRI images for 83 tumor scan tumor at pre-operation (pre-op), post-operation (post-op), and recurrence. (ii) 84 Representative pseudo-colored SERS images indicate the presence of each GSC marker in sEVs. 85 (iii) The changes of GSC score on GBM sEVs in response to the treatment and disease progression. 86

87 The figure was partly generated using Servier Medical Art.

88 Biomarker selection and validation

To capture GBM sEVs in peripheral blood, targeting CNS-related cell surface markers in sEVs is 89 an essential component of this study. CNS markers were selected through bioinformatic analysis 90 of the Genotype-Tissue expression (GTEx) and The Cancer Genome Atlas (TCGA) databases, 91 92 with cross-reference to all annotated membrane proteins in the UniProt database. Utilizing this approach, we developed a candidate list of membrane protein-coding genes (Figure 2A; 93 Supplementary, Figure S2 – complete heatmap) of which we selected ATP1B2, the β 2 subunit of 94 Na (+)/K (+) – ATPase expressed on glial cells[29], and solute carrier family 1 member 2 95 (SLC1A2), the astrocyte glutamate transporter EAAT2 for further analysis. [35, 36] These markers 96 were selected based on the suitability of appropriate antibodies targeting extracellular membrane 97 domains. Importantly, the RNA expression levels of ATP1B2 and EAAT2 are highly expressed in 98 99 brain tissue as well as low grade glioma (LGG) and high-grade GBM, compared to other normal tissues and cancers (Figure 2B; Supplementary, Figure S3). Given the hypothesis that sEVs 100 represent their cell-of-origin[23, 37], this differential expression underpins our approach to capture 101 limited GBM sEVs circulating in the blood. 102

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 2. CNS marker selection and validation. (A) Heatmap of top 20 CNS markers' RNA expression in TCGA and GTEx RNA-seq databases. Low expression is indicated in blue and high expression is indicated in yellow. (B) Tukey's boxplot indicating *ATP1B2* and *SLC1A2* (EAAT2) genes are highly expressed in normal brain and brain tumor tissues (GBM and low-grade gliomas, LGG) in TCGA and GTEx RNA-seq databases. (C) Primary GBM tumors (n = 31) were labeled

103

It is made available under a CC-BY-NC-ND 4.0 International license .

for ATP1B2 and EAAT2. Violin plots show the H-score labeling intensity across the cohort. Scale bar = $100 \mu m$.

111 We then clinically validated our bioinformatic selection of ATP1B2, EAAT2 through IHC of primary GBM tissues. For ATP1B2, low-intensity labeling reflected in low H-scores (mean 17.58 112 +/- 13.42; range 3.96 - 56.53) was detected across the cohort of tumors (Figure 2C). ATP1B2 113 labeling was observed diffusely spread throughout the dense neuropil, which normally contains 114 the nerve fibers and synapses and glial processes (Figure 2C). The labeling of ATP1B2 on control 115 tissues was also analyzed, in which strong ATP1B2 labeling of the cell membrane and cytoplasm 116 of photoreceptor cells; cells of the inner nuclear layer of the human retina; and positive labeling of 117 neuropil in human cortex (Supplementary, Figure S4A & B). Moderate EAAT2 labeling was 118 detected in tumor tissue for all cases of GBM (mean 75.89 +/- 28.88; range 18.13 – 119.69; Figure 119 2C). EAAT2 labeling was detected diffusely throughout the neuropil across the tumor sections 120 with occasional intense labeling of cell membranes and processes (Figure 2C). In the control 121 tissues, no EAAT2 expression were present in colonic crypts but in the human brain cortex strong 122 EAAT2 labeling was observed in astrocytes (Supplementary, Figure S4C & D). 123

After validating the selection of CNS markers, CD24, CD44, CD133 and EGFR were selected to 124 monitor different cell-like states of GSCs.[31] Specifically, scRNA-seq data has revealed that 125 CD24 is enriched in NPC-like GSCs, CD44 in MES-like GSCs, CD133 in OPC-like GSCs, and 126 EGFR is enriched in AC-like GSCs.[32, 38, 39] These surface GSC markers correlate with an 127 aggressive phenotype, poor survival, and associated with the rapid development of treatment 128 resistance.[31, 40-48] Transcriptomic expression based on the TCGA dataset confirmed that all 129 these markers are expressed in GBM (Supplementary, Figure S5). We then validated the 130 expression of CD44, CD133 and EGFR in GBM tumor tissues through IHC labeling 131 (Supplementary, Figure S4 & S6). EGFR (mean 173.01 ± 54.25 ; range 2.65 - 259.59) and CD44 132 (mean 130.58 \pm 43.84; range 57.66 – 205.24) were highly expressed across all the tumor tissues 133 134 with intense labeling of tumor cell membranes. Minimal labeling was detected in most GBM tumor sections for CD133 (mean 0.26 ± 0.80 ; range 0 - 4.20), with occasional positive labeling detected 135 sparsely throughout the tumor (Supplementary, Figure S6).[45] IHC labelling for CD24 was not 136 completed across the cohort of tumor tissues in this study, as the labelling of the cells and tissue 137 138 structures within the control tissues with several antibodies was not consistent with that reported

It is made available under a CC-BY-NC-ND 4.0 International license .

in the Human Protein Atlas. However, we chose to continue with CD24 in this study due to the
protein expression of GBM tissue in the Human Protein Atlas. Given the expression of these
biomarkers in GBM tissues based on TCGA dataset and IHC results, measuring the expression
changes of CD24, CD44, CD133 and EGFR on CNS derived sEVs from the same GBM patients
may help predict and track disease progression and treatment response.

144 Single nanoparticle analysis and GEMPAC marker validation

We then sought to validate our hypothesis that ATP1B2 and EAAT2 are specifically enriched on
the surface of GBM sEVs. To establish an *in vitro* model for GBM sEV analysis, the expression
of ATP1B2 and EAAT2 in three unique patient-derived GBM cell lines (BAH1, WK1, and FPW1;
representing classical or mesenchymal GBM subtypes[49]) were validated using flow cytometry.
In support of our bioinformatic selection of CNS candidates and IHC results, ATP1B2 and EAAT2
were highly expressed on the cell surface of three patient-derived GBM cell lines (Supplementary,
Figure S3C & D), and therefore as a result have the potential to be present on the surface of GBM

152 sEVs.

Next, we collected sEVs from our GBM patient-derived cell line panels and purified them through 153 size exclusion chromatography (SEC).[50] Purified sEVs were characterized by nanoparticle 154 tracking analysis (NTA), showing a characteristic modal size of 90-100 nm (Supplementary, 155 Figure S7A). We then used transmission electron microscopy (TEM) to visualize the morphology 156 of purified sEVs (Supplementary, Figure S7B). Following this, the surface expression of the 157 canonical sEV tetraspanin CD9 and CD63 were measured by nanoflow cytometry (nanoFCM) 158 (Supplementary, Figure S7C), and western blot demonstrated the presence of internal HSP70 and 159 absence of the endoplasmic reticulum-associated molecular chaperone, calnexin (Supplementary, 160 Figure S7D). 161

We next evaluated if the expression of ATP1B2 and EAAT2 was specifically enriched on GBM sEVs. As we hypothesized, cell-of-origin-specific enrichment of ATP1B2 and EAAT2 were detected on GBM sEVs (14.22% and 32.37% respectively), while MDA-MB-231-derived breast cancer sEVs (-ve) contained negligible levels of both CNS markers (Figure 3A; Supplementary, Figure S8). Next, we evaluated the expression of the GSC markers CD24, CD44, CD133, and

It is made available under a CC-BY-NC-ND 4.0 International license .

167 EGFR on the surface of GBM sEVs. Using single nanoparticle analysis by nanoFCM, we found

high levels of CD24 (19.1%) and EGFR (23.6%), moderate levels of CD44 (8.17%) and low levels

of CD133 (4.06%) (Figure 3B; Supplementary, Figure S8).

After validating that we have identified a unique CNS signature for the analysis of GBM sEVs. 170 we sought to develop an approach that meets the requirements for sensitive and specific detection 171 of GBM sEVs that is clinically translatable (GEMPAC). We carried out a specificity assay to 172 examine the functionality and specificity of the GEMPAC platform. Each electrode of the 173 GEMPAC was functionalized with dual capture antibodies, anti-ATP1B2 and anti-EAAT2, for 174 capturing GBM sEVs. A purified total of 5×10^8 sEVs particles were then applied to individual 175 electrodes and subsequent AC-EHD nanomixing facilitated specific binding of GBM sEVs while 176 simultaneously reducing non-specific interactions.[34] Following this, unique SERS nanotags 177 were applied to each electrode to detect targeted markers on captured sEVs simultaneously. 178 Pseudo-colored SERS mapping images for GBM sEVs are shown in Figure 3C. High expression 179 of both ATP1B2 and EAAT2 was observed for the GBM cell line-derived sEVs (BAH1, WK1, 180 and FPW1), with minimal signals detected for non-GBM sEVs (MDA-MB-231 breast cancer) and 181 an sEV-free control (Figure 3D). Expression of the putative prognostic GSC markers CD24, CD44, 182 CD133 and EGFR were also detectable in the GBM sEVs and absent from other samples due to 183 the specific capture of GBM sEVs (Figure 3D). As a result, combining these markers could 184 distinguish GBM sEVs from other malignancies. 185





Fig. 3. Expression of selected markers on GBM sEVs by single nanoparticle analysis and GEMPAC. (A) Single nanoparticle analysis by nanoFCM shows the expression of CNS markers (ATP1B2 and EAAT2) in breast cancer cell line MDAMB231 (-ve) and WK1 sEVs. Average histogram measurements are the average expression of 3 GBM cell line sEVs (WK1, BAH1, FPW1). (B) Single nanoparticle analysis by nanoFCM shows the expression of GSC markers

It is made available under a CC-BY-NC-ND 4.0 International license .

(CD24, EGFR, CD44, and CD133) as representative nanoFCM images and average histogram 192 measurements in three GBM cell lines. (C) Representative Raman images for all of marker's 193 detection in GBM cell lines using GEMPAC. Scale bar = $10 \mu m$. (D) Raman intensity 194 measurements of sEVs from each GBM cell line with different SERS nanotags; DTNB-ATP1B2 195 (red), MBA-EAAT2 (blue), TFMBA-CD44 (green), MPY-CD133 (yellow), TFMBA-EGFR 196 (purple) and MPY-CD24 (grey). MDA-MB-231 breast cancer cells and EV-free medium were 197 used as negative controls to show biomarker specificity. Data are represented as mean \pm standard 198 199 error.

200 Analysis of GBM patient sEVs sampled before and after surgical resection by GEMPAC

Given the specificity of the GEMPAC assay for analyzing GBM sEVs, we next sought to 201 202 investigate the composition of GBM sEVs in the blood of GBM patients. Pre- and post-op blood plasma were sourced from GBM patients. sEVs were purified from plasma using SEC and 203 204 analyzed with TEM and nanoFCM to confirm size distribution and concentration of particles (Figure 4A & B). There were no significant differences in sEV size and concentration at the two 205 time points (p > 0.05) (Figure 4B), indicating that these specific sEV properties provide little 206 prognostic or diagnostic information overall. Therefore, our approach of profiling the phenotype 207 208 of GBM sEVs using GEMPAC may offer more insights for diagnostic and prognostic applications in GBM patients. 209

210 To address this, we successfully profiled GBM sEVs with our GEMPAC platform by quantifying the composition of ATP1B2, EAAT2, CD24 CD44, CD133, and EGFR (Representative patient, 211 Figure 4C). To understand changes in circulating GBM sEVs, each GSC marker was normalized 212 by the CNS markers (ATP1B2 and EAAT2) and combined into the GEMPAC score to provide 213 insights into the tumor burden of GBM patients. A total of 36 patients were profiled to investigate 214 215 if the GEMPAC score changed after surgical resection. There was no significant change in the GEMPAC score before and after the surgery (p > 0.05) (Figure 4D), and the phenotypic 216 composition of GSC markers on circulating GBM sEVs remained the same (Figure 4E & F). 217

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 4. Analysis of sEVs in plasma before and after surgical resection in GBM patients. (A) 219 GBM patient samples (n = 36) sEV size distribution. (B) GBM sEV concentration in pre-op and 220 221 post-op. (C) Raman intensity measurements of each marker with SERS images in pre-op and postop in the representative GBM patient, DTNB-ATP1B2 (red), MBA-EAAT2 (blue), TFMBA-222 CD44 (green), MPY-CD133 (yellow), TFMBA-EGFR (purple), and MPY-CD24 (grey). Data are 223 represented as mean \pm standard error (n = 4). (D) All the GBM stem cell markers were normalized 224 by CNS markers and sum as GEMPAC score. Comparison of GEMPAC score between pre-op and 225 post-op. The proportion of each normalized GSC marker in (E) pre-op and (F) post-op. Kaplan-226 Meier plots of overall survival by GEMPAC score. Survival outcome differences in pre-op (G) 227 and post-op (H). (I) ROC curve analysis for GEMPAC score between short and long overall 228 survival groups. 229

218

It is made available under a CC-BY-NC-ND 4.0 International license .

Next, we investigated if the GEMPAC score was able to predict overall survival in a cohort of 24 230 patients who received only standard care temozolomide (TMZ) and radiotherapy (RT). Patients 231 were categorized into either high (> median GEMPAC score) or low (< median GEMPAC score) 232 groups. Before surgical resection there was no correlation in overall survival (p = 0.4936) (Figure 233 4G), however, after surgical resection, patients with a high GEMPAC score had significantly 234 shorter survival compared to patients with a low GEMPAC score (p = 0.0055) (Figure 4H). To 235 investigate the sensitivity and specificity of the GEMPAC score for predicting overall survival, a 236 1-year overall survival was assessed by receiver operating characteristic (ROC) curves. In this 237 context, the area under the curve (AUC) for predicting overall survival after surgical resection 238 (post-op) was 0.79 (95% CI 0.6-0.98) (Figure 4I). These results indicate the GEMPAC score from 239 circulating GBM sEVs could predict patients' survival after surgery, likely reflecting the 240 241 remaining tumor burden after surgical resection which is a predictor of survival after resection.[51]

242 Longitudinally monitoring radiological recurrence and sEV evolution by GEMPAC

Our understanding of glioblastoma heterogeneity is limited in terms of the cellular landscape at 243 various stages of disease evolution during standard of care therapies. Clinical progress is restricted 244 due to this limited knowledge of GBM evolution and inability to measure tumor evolution in real-245 time during therapy. To investigate evolutionary changes during GBM progression, we isolated 246 and profiled GBM sEVs from the plasma of 12 GBM patients with longitudinal blood samples. 247 We subsequently evaluated the relative expression of CNS-related markers ATP1B2, EAAT2, and 248 GSC-related markers CD24, CD44, CD133, and EGFR in sEVs before and during therapy. 249 Furthermore, the expression of ATP1B2, EAAT2, CD44, CD133, and EGFR in primary tumor 250 tissues were confirmed by IHC (n = 11) (Supplementary, Figure S9) to confirm that these markers 251 were expressed in the primary tumor. We then evaluated the results of GEMPAC in relation to 252 clinical interpretation of response to treatments in conjunction with MRI and where available with 253 254 positron emission tomography (PET) scans.

It is made available under a CC-BY-NC-ND 4.0 International license .





256



257 The comparison of GEMPAC score between patients that had radiological recurrence (RR) less

It is made available under a CC-BY-NC-ND 4.0 International license .

than 300 days and more than 300 days. Data are represented as mean ± standard deviation. *** p 258 < 0.001. (B) Kaplan-Meier plots of overall survival demonstrate MRI detected radiological 259 recurrence is associated with overall survival. (C) Representative longitudinal case showing 260 detection of progression with the GEMPAC analysis before MRI. (i) MRI images and SERS 261 mapping images of LP1. Red arrows indicated tumor location. Scale bar = $10 \mu m$; (ii) GEMPAC 262 score for LP1 before and during the treatment indicating progression (red area) before MRI 263 detected recurrence at 41 weeks; (iii) Normalized GSC-related protein, CD24 (grey line), CD44 264 (green line), CD133 (yellow line), and EGFR (purple line) composition changes throughout 265 treatment, indicating a significant increase in the MES-like GSC CD44 markers. (Data are 266 represented as mean \pm standard error (n = 4). Significant differences are represented by different 267 letters (p < 0.05). (D) Representative longitudinal case of responding to the TMZ therapy. (i) MRI 268 269 images and SERS mapping images of LP2. Red arrows indicated tumor location. Scale bar = 10 μ m; (ii) GEMPAC score of LP2 before and during the treatment, with the blue area representing 270 271 a therapeutic response; (iii) Normalized GSC-related protein composition, CD24 (grey line), CD44 (green line), CD133 (yellow line), and EGFR (purple line) changes throughout the treatment, 272 273 indicating a decrease in the MES-like GSC CD44 marker. Data are represented as mean ± standard error (n = 4). 274

We explored the capabilities of the GEMPAC score in monitoring disease progression or a positive 275 therapeutic response. Interestingly, when we analyzed the GEMPAC score in patients that had 276 radiological recurrence detected by MRI within 300 days, we identified a significantly increased 277 GEMPAC score at 5-6 weeks, and cycle 5 of TMZ treatment (Figure 5A). Importantly, there was 278 no significant difference in the total abundance of CNS-derived sEVs throughout treatment 279 280 (Supplementary, Figure S10), highlighting the importance of measuring the total GSC stem cell marker expression to detect therapeutic response. Disease progression in these patients detected 281 by MRI was correlated to a significantly reduced overall survival (Figure 5B), indicating that 282 monitoring patients during therapy with the GEMPAC assay could accurately determine 283 therapeutic response. 284

To further explore and characterize heterogeneity and evolution within malignant cell populations, we assessed the relative GSC protein composition of circulating GBM sEVs at all timepoints (Figure 5C & D; Supplementary, Figure S12). We observed changes in the landscape of GSC-

It is made available under a CC-BY-NC-ND 4.0 International license .

related sEV composition at various stages of disease evolution and during TMZ therapy. 288 Specifically, in representative Longitudinal Patient 1 (LP1), MRI indicated tumor debulking and 289 recurrence, and our GEMPAC assay tracked evolutionary changes of GBM sEVs throughout 290 treatment (Figure 5C (i-iii)). In particular, at cycle 5, an elevated GEMPAC score (Figure 5C(i)) 291 was driven by a subtle increase in the OPC-like GSC CD133 and a significant increase in the MES-292 like CD44 GSC marker (Figure 5C(iii)) before radiological recurrence was detected at 41 weeks, 293 suggesting disease progression is driven by a clinically relevant glioblastoma stem cell 294 subpopulation consistent with previous studies.[43, 45, 52] Similarly, multiple patients (LP3, 5-7) 295 also exhibited similar evolutionary changes in circulating sEVs with elevated GEMPAC scores 296 being detected in sEVs before MRI indicated tumor progression (Supplementary, Figure S12 & 297 S13). 298

We next wanted to assess if our GEMPAC assay could monitor positive response to treatment in 299 GBM patients. Our GEMPAC assay detected alterations in the relative expression of CD24, CD44, 300 CD133, and EGFR throughout treatment in representative Longitudinal Patient 2 (LP2) (Figure 301 5D (i-iii)). LP2 responded positively to TMZ+RT which was recapitulated with our GEMPAC 302 assay showing a dynamic reduction in the GEMPAC score from week 5. This was largely driven 303 by reduced levels of the GSC markers CD44 and EGFR. The response our GEMPAC assay 304 detected was further validated with an overall survival of 94 weeks in this patient. Additionally, 305 our GEMPAC assay consistently measured positive response to treatment with RT and TMZ in 306 additional longitudinal patients LP4, 8 & 9 (Supplementary, Figure S12 & S13). 307

Longitudinally monitoring evolution of GSC-related protein composition of GBM sEVs driven by therapy

To directly link the GEMPAC capture and analysis of GBM sEVs to evolutionary changes within the tumor, we compared patients receiving EGFR targeting ABT-414 (depatuxizumab mafodotin) and TMZ+RT (n = 4), versus patients receiving TMZ+RT (n = 5) with matched collection timepoints. Although there was no difference in the GEMPAC score in patients receiving ABT-414 (Supplementary Figure S11), our GEMPAC assay detected evolutionary changes of the tumor through changes in the phenotypic composition of sEVs (Figure 6; Supplementary, Figure S13). In particular, the reduced EGFR expression in a recurrent tumor of a patient treated with ABT-414

It is made available under a CC-BY-NC-ND 4.0 International license .

compared to TMZ+RT alone (Figure 6A & B), correlated with what we observed in our GEMPAC assay with a significant decrease in EGFR on sEVs (Figure 6C). Due to the molecular and genomic heterogeneity leading to GBM evolution, various subpopulations of cancer cells with stem-like properties following radiotherapy and chemotherapy are capable of driving resistance. In this case, GEMPAC observed a significant increase in the MES-like CD44 GSC marker at cycle 3 and 5 in patients receiving ABT-414 (Figure 6D). Therefore, although ABT-414 suppressed EGFR subpopulations, there was limited therapeutic efficacy against mesenchymal subpopulations.



324

It is made available under a CC-BY-NC-ND 4.0 International license .

325 Fig. 6. GEMPAC assay tracks tumor evolution by GSC protein composition in circulating

GBM sEVs. Representative IHC staining of EGFR in primary and recurrent tumors of patients 326 receiving either TMZ+RT (A, LP3) or ABT-414 with TMZ+RT (B, LP4). Red arrow indicates the 327 tumor location. SERS images scale bar = $10 \,\mu\text{m}$. IHC scale bar = $100 \,\mu\text{m}$. (C-F) Each GSC-related 328 protein expression changes throughout treatment shows significant knockdown of EGFR and 329 increase of CD44 expression in circulating GBM sEVs. * p < 0.05; *** p < 0.001. Solid lines are 330 the patients receiving TMZ+RT (n = 5) and dotted lines are patients receiving ABT-414 with 331 TMZ+RT (n = 4). Data are represented as mean \pm standard deviation. Black arrow indicates when 332 the ABT-414 starts. 333

In addition to our GEMPAC assay measuring treatment efficacy of TMZ+RT, response to the bevacizumab could also be analyzed. Specifically, GEMPAC detected a decrease in GSC markers on circulating sEVs after bevacizumab treatment (Supplementary, Figure S14A). GEMPAC again monitored evolution of the GSC marker composition on GBM sEVs with reduced levels of CD44, CD133 and EGFR at 11 weeks after the start of bevacizumab treatment (Supplementary, Figure S14B & C). Overall, these results demonstrate that GEMPAC has the potential to monitor GBM evolution and therapeutic response in patients being treated with a range of drugs.

341 **DISCUSSION**

In the present study, we developed a nanodiagnostic platform, termed GEMPAC, to provide realtime readout of GBM patients under therapy through analysis of sEVs in blood. A key finding from our work is the identification that sEVs derived from GBM tumor cells can be captured and interrogated in patients. As a result, we were able to monitor the emergence of proliferating GSCs from circulating sEVs to dynamically monitor therapy response and tumor evolution.

The complexity and degree of genomic and cellular heterogeneity of high-grade gliomas such as GBM is only recently being fully comprehended.[53] This is due, in large part, to technological advancements in single-cell profiling leading to numerous discoveries regarding tumor heterogeneity and the revelation of cellular states; specifically MES-like, NPC-like, AC-like, and OPC-like within malignant brain tumors.[31, 54] However, clinical progress in GBM management will be limited without sophisticated approaches to monitor tumor evolution and progression

It is made available under a CC-BY-NC-ND 4.0 International license .

throughout treatment cycle.[55, 56]Advancements in this area have been limited due to difficulties in sampling longitudinal surgical biopsies, and therefore can only be addressed through liquid biopsies in combination with highly sensitive analytical techniques. In addition to the high sensitivity, the GEMPAC has further advantages for liquid biopsy testing in GBM patients as the analysis of sEVs only requires small volumes that can be routinely collected and cryopreserved. This makes sample collection feasible particularly for patients that do not have access to MRI, as they can be monitored regularly regardless of geographical distribution.

At least three of the cellular states within GBM have the capability of propagating tumors in 360 preclinical models, including MES-like, NPC-like and OPC-like.[31-33] Previous studies have 361 proposed quiescent GSCs with MES properties start proliferating in response to therapy and are a 362 driver of disease recurrence. [56, 57] Although the basis for this is unclear, we were able to observe 363 the emergence of a MES-like signature in GBM sEVs by the elevation of CD44 throughout 364 treatment in patients. This elevated level of CD44 on GBM sEVs was associated with disease 365 progression, suggesting that the MES-like GSCs expansion driving recurrent disease[53, 58], can 366 also be monitored dynamically during therapy with the GEMPAC. Another observation in our 367 study was the emergence of elevated CD133 expression on circulating GBM sEVs in a 368 subpopulation of patients, suggesting the expansion of CD133⁺ GSCs. These findings support the 369 premise that CD133⁺ stem cell expansion, which typically have the highest degree of resistance to 370 TMZ [59], persist throughout treatment and could potentially be responsible for the initiation of 371 372 tumor recurrence.

During our analysis, we did not observe an increase associated with recurrent disease in sEV GSC 373 markers CD24 and EGFR during therapy. Although EGFR is a striking feature of GBM, elevated 374 EGFR expression is associated with tumors with a phenotype dominated by AC-like cells. In terms 375 of EGFR expression in GBM, there is evidence in our data of GBM evolution in response to 376 therapy. In particular, circulating sEVs in patients treated with ABT-414 indicated a shift to a 377 MES-like cellular state with downregulation of EGFR and elevation of CD44, an observation that 378 was seen in the evolutionary changes of the recurrent tumor. There is evidence that a phenotypic 379 shift to a MES phenotype can be driven by multiple factors, including inherent resistance to 380 therapy; a phenotypic shift among individual cells; or changes in the proliferative rates among cell-381

It is made available under a CC-BY-NC-ND 4.0 International license .

likes GSC states of GBM.[31, 60] In our study, we were able to observe these changes in real-time
as sEVs from MES-like were increasingly abundant following therapy.

Patients often deteriorate rapidly once treatment resistance develops and having an early signal 384 could significantly change treatment by accelerating testing of new drugs, or drug-radiation 385 combinations. Collectively, our GEMPAC platform opens a window for monitoring brain 386 pathologies during therapy and offers a unique view of changes in the GBM sEV landscape at 387 various stages of disease evolution. This assay has potential broad clinical implications and could 388 be utilized to not only predict treatment outcomes, but also determine the phenotypic heterogeneity 389 of GBM. The capability of monitoring the emergence of specific GSCs associated with distinct 390 GBM cellular states might be therapeutically important as targeted elimination of specific GSCs 391 might have clinical benefit. As a result, we envisage with future validation in larger clinical 392 cohorts, the high sensitivity of our GEMPAC platform could be utilized for predicting optimal 393 treatment approaches in new areas of therapeutic development for GBM patients. 394

It is made available under a CC-BY-NC-ND 4.0 International license .

395 MATERIALS AND METHODS

396 Clinical sample acquisition

This study was approved by the Human Research Ethics Committee of the University of Newcastle 397 (H-2020-0231). Informed consent was received from all patients. Blood was obtained from non-398 399 fasted patients before surgery, post-surgery (1-7 days) and at the time of treatment in EDTA-coated tubes. Whole blood was centrifuged twice to deplete platelets and separate plasma. Plasma was 400 then aliquoted and stored at -80° C until use. Formalin-fixed paraffin-embedded tumor tissue from 401 surgical resection was sourced from the Mark Hughes Foundation Brain Bank facilitated by the 402 403 NSW Regional Biospecimen Services for 36 cases of glioblastoma (Supplementary, Table S1). A block containing maximal tumor content was chosen from each patient and diagnosis of 404 glioblastoma confirmed on H&E sections by a neuropathologist (Dr. Ricardo Vilain, Hunter Area 405 Health Service). Clinical information is available in Supplementary, Table S1 including age, 406 407 gender, treatment information, MGMT promoter methylation status, overall survival information, isocitrate dehydrogenase (IDH) status, EGFR status, glial fibrillary acidic protein (GFAP) status, 408 and alpha-thalassemia/mental retardation, X-linked (ATRX) status. 409

410 Bioinformatic analysis to identify brain specific surface proteins

Our objective was to identify robust brain-specific markers for the capture of CNS-specific sEVs. 411 We conducted a bioinformatic analysis to select CNS-specific markers based on data sourced from 412 413 The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx), and the UniProt database as previously described.[61] This integration enabled a comprehensive investigation of 414 markers specific to the brain. Subsequently, we utilized The Human Protein Atlas, to refine the 415 selection of markers with an extracellular domain and selected candidates with medium to strong 416 417 immunohistochemistry staining. Following this, the surface markers ATP1B2 and EAAT2 were selected based on the availability of suitable antibodies that target the extracellular domain of each 418 419 protein.

420 Cell culture

It is made available under a CC-BY-NC-ND 4.0 International license .

Primary patient-derived Q-Cell GBM cell lines were obtained under MTA from QIMR Berghofer Medical Research Institute.[49, 62, 63] BAH1 (QIMR-B001), WK1 (QIMR-B012), and FPW1 (QIMR-B002) were cultured in serum-free KnockOut[™] DMEM/F-12 medium supplemented with StemPro® neural supplement (Thermo Fisher Scientific), epidermal growth factor (EGF) (20 ng/mL), and fibroblast growth factor (FGF) (10 ng/mL) (StemPro[™] NSC SFM). Cells were maintained as an adherent monolayer on a basement membrane of Matrigel (Corning).[49] For sEV isolation, BAH1, WK1, and FPW1 cells were cultured using Cytodex-1 microcarriers.

428 **Preparation of microcarriers**

429 Cytodex-1 microcarriers (Cytiva) were prepared according to the manufacturer's guidelines. 430 Briefly, dry Cytodex-1 microcarriers were hydrated with PBS (50 ml/g Cytodex-1) for at least 4 431 hours and washed 2 times with the same volume of PBS before being autoclaved (121 °C, 15 psi 432 for 30 mins). Microcarriers were then coated with Matrigel (1:30) before being washed and 433 equilibrated in StemProTM NSC SFM.

434 Cell line sEV medium collection

BAH1, WK1, and FPW1 cells were seeded at 2x10⁵ cells/mL containing 2 g/L of Cytodex-1 435 microcarriers in 1/3 of the final volume of StemPro[™] NSC SFM with periodic stirring at 37 °C 436 for 3 hours. After 3 hours, the volume of the culture was increased to the final volume and 437 continuous shaking commenced at 90 RPM to keep the microcarriers in suspension. Cells were 438 cultured for 72 hours before the culture medium was collected and centrifuged at 500 $\times g$ for 10 439 min and then filtered through a 0.22 µm filter to remove cell debris and large EVs. The filtered 440 culture media was then concentrated using tangential flow filtration as previously described in 441 detail.[64] Briefly, media was prepared for sEV purification by concentrating with a sterile 442 443 Minimate 300kDa Omega Membrane (Pall Corporation) Tangential Flow Filtration Capsule to approximately 20 mL with continuous diafiltration (5 diafiltration volumes), and further 444 445 concentrated with a Centricon Plus-70 100 kDa (Merck) to approximately 500 µL before being purified with SEC. 446

447 **sEV purification**

It is made available under a CC-BY-NC-ND 4.0 International license .

sEVs were purified from GBM cell culture medium and patient plasma samples using SEC as 448 previously described in detail. [50, 64] Patient plasma samples was thawed from -80°C and kept 449 on ice. Aliquots of 500 µL were centrifuged at $10,000 \times g$ for 10 minutes at 4°C to pellet any 450 remaining cellular debris or larger particles. Concentrated culture medium or clarified patient 451 samples were subsequently applied to Izon qEV Original 70 nm columns (Izon Science) and eluted 452 in filtered phosphate-buffered saline (PBS, Sigma-Aldrich). Following the void volume, the 453 following 1.6 mL of sEV-enriched fractions were concentrated to \leq 50 µL using Amicon Ultra-4 454 10 kDa MWCO columns (Merck) at 3,500 \times g for approximately 45 minutes at 4°C. The 455 concentrated sEV isolates were aliquoted and stored at -80°C. 456

457 Nanoparticle tracking analysis (NTA)

NanoSight N300 (NanoSight Nanoparticle Tracking and Analysis Release Version Build 3.4) was used as previously published [64]. Briefly, the samples were diluted with PBS to a particle range of 50 – 100 particles per frame. Samples were analyzed at 25°C. The camera level was set to provide sufficient contrast to identify particles while minimizing background noise and samples were recorded in triplicate.

463 Measurement of sEV Size and Concentration using nanoFCM

Purified sEV samples were analyzed by nanoFCM equipped with 488 and 640 nm 464 lasers.Concentration and fluorescence measurements were calibrated with 250 nm silica 465 466 nanospheres labelled with fluorochromes at 20 mW laser power, 0.2% SS decay and 1 kPa sampling pressure. The particle size distribution of sEVs was calibrated at 10 mW laser power, 467 10% SS decay and 1 kPa sampling pressure using a four-modal standard silica nanoparticle 468 cocktail (68~155 nm) which has a similar refractive index to EVs.[65] Positive particles were gated 469 470 based on a negative control of PBS or the respective fluorescent antibody to adjust for background fluorescence 471

472 sEV immunofluorescent staining for nanoFCM

473 Approximately 1×10^9 total sEV particles were incubated with either anti-ATP1B2 (PA526279, 474 Thermo Fisher Scientific), anti-EAAT2 (NOVNBP120136, Novus), anti-CD9 APC (17-0098-42,

It is made available under a CC-BY-NC-ND 4.0 International license .

Thermo Fisher Scientific), anti-CD24 (ab134375, Abcam), anti-EGFR (ab231, Abcam), anti-475 CD44 Alexa Fluor 488 (103016, BioLegend), or anti-CD133 Alexa Fluor 488 (FAB11331G, R&D 476 Systems) in 50 µL of PBS, for 1 h at 37 °C. Labeled sEVs were diluted with 1 mL of PBS and 477 ultracentrifuged at $110,000 \times g$ for 30 min using an Optima MAX-XP Benchtop Ultracentrifuge 478 (Beckman-Coulter) TLA-100.3 rotor (k-Factor 14). Samples labeled with anti-ATP1B2 and anti-479 EAAT2, anti-EGFR, and anti-CD24 were subsequently incubated with goat anti-rabbit IgG H&L 480 APC (ab130805, Abcam), anti-rat IgG2a heavy chain Alexa Fluor 488 (ab172332, Abcam), and 481 anti-mouse IgG Alexa Fluor 488 (ab150113, Abcam) respectively for 1 h at 37 °C, and 482 ultracentrifuged as before. The supernatant was removed and the sEV pellet was resuspended in 483 50 µL of filtered PBS for analysis with the nanoFCM equipped with 488 and 640 nm lasers. Data 484 was analyzed using FlowJo version 10.8.1. 485

486 Western blot

487 GBM patient-derived cells (BAH1, WK1, and FPW1) and their sEVs were reduced and denatured by Laemmli buffer and 2-mercaptoethanol (Bio-Rad) for 5 minutes at 95°C. Proteins were resolved 488 by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene 489 fluoride membranes (Bio-Rad). The membranes were blocked with 5% skim milk in PBS-T (0.1% 490 491 Tween-20) for 30 minutes at room temperature (RT). Primary antibodies, anti-Calnexin (2679, Cell Signaling) and anti-Hsp70 (610608, BD Biosciences), were applied at the recommended 492 dilutions for 1 hour of incubation at RT. After incubation, the membranes were washed five times 493 with PBS-T and incubated with a HRP-conjugated secondary antibody for 1 hour at RT. The 494 membranes were then washed five times with PBS-T and visualized using enhanced 495 chemiluminescence reagent (Clarity Western ECL Substrate, Bio-Rad) and the Bio-Rad 496 ChemiDoc Imaging System. 497

498 **TEM**

For TEM analysis, 2.5 μ L of isolated sEVs (1 × 10¹¹ particles/mL) were fixed with an equal volume of 2% glutaraldehyde for 30 minutes at RT. Subsequently, 5 μ L of fixed sample was loaded on Formvar/carbon-coated electron microscopic grids (Electron Microscopy Science) and incubated for 15 minutes and excess liquid was removed by blotting. The grid was washed three times by

It is made available under a CC-BY-NC-ND 4.0 International license .

brief contact with 100 μ L of Milli-Q water, followed by blotting to remove excess liquid. To contrast the sample, the grid was negatively stained with 30 μ L of 2% uranyl acetate (w/v) for 5 minutes and excess fluid was removed by blotting gently. Grids were left to air dry and observed using transmission electron microscopy (Hitachi HT7700) at 100 kV.

507 **GEMPAC Chip fabrication**

The GEMPAC device with 28 asymmetric electrodes was fabricated with standard 508 509 photolithography as previously reported. [66, 67] The electrode pattern was designed using Layout Editor L-Edit V15 (Tanner Research) and written on 5-inch soda lime chrome masks (Shenzhen 510 511 Qingyi Precision Mask Making) using a direct write system µPG 101 (Heidelberg Instruments). Then, a clean 4-inch Boroflat wafer (Bonda Technology Pte Ltd) was spin-coated with a negative 512 photoresist AZnLOF 2020 (Microchemicals GmbH) at 3000 rpm for 30 seconds. After a soft bake 513 for 2 minutes at 110 °C, the wafer was UV-exposed with the above prepared mask at a constant 514 515 dose of 200 mJ cm⁻¹ using a mask aligner (EVG 620, EV Group, St Florian am Inn), following a post-exposure bake for 1 minute at 110 °C and wafer development for 30 s using an AZ726 MIF 516 Developer (Microchemicals GmbH). The gold electrodes were then created by deposition of 10 517 nm Titanium and 200 nm gold using a Temescal FC-2000 Deposition System (Ferrotec) and 518 519 overnight lift-off in Remover PG (Microchemicals GmbH). The wafer carrying the gold electrode structures was rinsed with isopropanol and dried under a flow of nitrogen. 520

To accommodate the liquid sample analysis, a 4 mm-thick polydimethylsiloxane (PDMS) slab with microfluidic well structures was manually aligned to electrodes of the device. The PDMS slab was prepared by curing activated silicon elastomer solution (Sylgard 184, Dow) for 2 h at 65 °C. The PDMS slab was then punched with 5 mm-diameter wells and thermally bonded to the device overnight at 65 °C.

526 SERS nanotag synthesis and functionalization

60 nm gold nanoparticles were synthesized through citrate reduction of gold (III) chloride trihydrate (HAuCl₄, Sigma-Aldrich).[68] 0.01% (w/v) of HAuCl₄ was added into 100 mL Milli-Q water and heated till boiling. 1 mL of 1% (w/v) of trisodium citrate dehydrate (Univar Solutions) was quickly added into the boiling solution with constant mixing and kept at a boil for 20 minutes

It is made available under a CC-BY-NC-ND 4.0 International license .

with constant mixing. To synthesize SERS nanotags, 1 mL of gold nanoparticle solution was 531 incubated with 2 µL of 1 mM Dithiobis (succinimidyl pro) (DSP, Thermo Fisher Scientific) and 532 10 µL of a 1 mM Raman reporter (Sigma-Aldrich) for 5-7 h with gentle shaking (350 rpm) at RT. 533 After that, the solution was centrifuged at 5400 $\times g$ for 10 min and resuspend in 200 µL of 0.1 mM 534 PBS buffer. The Raman intensity for each SERS nanotag was measured. After that, the solution 535 was then incubated with 1 µg of paired antibodies, anti-ATP1B2 (PA526279, Thermo Fisher 536 Scientific), anti-EAAT2 (NOVNBP120136, Novus Biologicals), anti-CD24 (ab134375, Abcam), 537 anti-EGFR (ab231, Abcam), anti-CD133 (130108062, Miltenyi Biotec) and anti-CD44 538 (14044182, Thermo Fisher Scientific) for 30 minutes at RT. The solution was then centrifuged at 539 $600 \times g$ for 6 minutes to remove excess antibodies. After that, SERS nanotags were resuspended 540 in 0.1% (w/v) bovine serum albumin (BSA) to block non-specific binding. The patterns of Raman 541 reporters with antibodies were DTNB-ATP1B2, MBA-EAAT2, TFMBA-CD44, and MPY-542 CD133. 543

544 **GEMPAC functionalization and operation**

20 µL of 5 mM DSP were incubated at the center circular electrode for 30 min at RT. Following 545 this, electrodes were washed once with absolute EtOH followed by 3 washes of $1 \times PBS$. Next, 20 546 μ L of 10 μ g/mL of capture antibodies for 2 h at RT were incubated on the electrode. The electrode 547 was then blocked with 5% (w/v) BSA in PBS and incubated overnight at 4 °C. After blocking, 548 electrodes were washed 3 times with 1% (w/v) BSA in PBS before sample addition. A total of $5 \times$ 549 10^8 sEVs in 50 µL was added into the circular electrode and an alternative current field of 800 mV 550 and 599 Hz was applied for 45 minutes. Electrodes were then washed 3 times with 1% (w/v) BSA 551 in PBS before the addition of 20 μ L of SERS nanotags (1 in 25 dilutions in 1% (w/v) BSA in PBS). 552 The electric field with same conditions as above was carried out for 20 min. Electrodes were then 553 finally washed 3 times with 1% (w/v) BSA in PBS. 554

555 SERS mapping and analysis

556 Samples were analyzed and recorded by Witec alpha 300 R micro-spectrometer using a 632.8 nm 557 excitation wavelength from a HeNe laser (laser power 4 mW). The integration time for 558 measurement is 0.05 s on each electrode. Each sample has 2-3 separate electrodes as technique

It is made available under a CC-BY-NC-ND 4.0 International license .

replicates. Each electrode was measured with two areas of $60 \,\mu\text{m} \times 60 \,\mu\text{m}$ (60 pixels $\times 60 \,\text{pixels}$)

squares using a $20 \times$ objective. The signal peak was based on each Raman reporter's signature

561 peak, MPY – 1000 cm⁻¹, MBA – 1078 cm⁻¹, DTNB – 1333 cm⁻¹, and TFMBA – 1378 cm⁻¹. The

signal intensity was calculated and representative of each protein marker's expression level onsEVs.

505 B**L** (5.

564 Immunohistochemistry

Formalin-fixed paraffin-embedded tumor tissue was sliced into 4 µm full face sections and 565 processed for 3',3'-diaminobenzidine (DAB) immunohistochemistry using a Ventana Discovery 566 567 Ultra (Roche) by the HCB. 31 out of 32 patients' tissues were available for IHC staining. Sections were labeled with rabbit antibodies directed at either EAAT2 ATP1B2, EGFR, CD133 and CD44 568 (Supplementary, Table S2). All steps, from baking to chromogen addition were performed 569 automatically by the instrument. Tissue sections were baked to slides and deparaffinized, and 570 571 antigen retrieval then occurred at 95 °C / pH 9 with a total incubation time of 24 minutes before the addition of the primary antibody. The addition of the primary antibody was followed by a 32-572 minute incubation at 36 °C. Slides were then incubated with a secondary antibody – Anti-Rabbit 573 HQ (Roche), for 20 minutes at 36 °C. Positive control and negative control tissues were included 574 in each batch of slides to confirm the specificity of antibody labeling. 575

576 **Quantitative IHC analyses**

GBM tissue slides were digitally scanned using the Aperio[™] Digital AT2 Pathology System 577 (Leica Biosystems) at $40 \times$ absolute resolution. Quantitative IHC analyses were performed using 578 the HALO[™] image analysis platform (version 3.0, Indica Labs, NM). Tissue classification 579 algorithms were used to differentiate tissue regions, such as tumors, necrosis, adjacent normal 580 581 brain, followed by quantification of pixel intensity values corresponding to DAB staining of protein biomarkers. Area quantification algorithm, which detects biomarker expression across the 582 whole tumor, as well as the cytonuclear algorithm, which quantifies based on cellular 583 compartment, were both used dependent on protein biomarker localization. The labeling intensity 584 585 of each marker was measured across four representative areas of each tumor and average H-scores for each biomarker for each tumor was calculated as: H-score = $(1 \times \%)$ weak positive tissue) + $(2 \times \%)$ 586

It is made available under a CC-BY-NC-ND 4.0 International license .

587 x % moderate positive tissue) + $(3 \times \% \text{ strong positive tissue})$ with a range of 0 - 300. H-scores 588 were then used to create distribution plots to show biomarker intensity across the cohort of 589 glioblastoma cases.

590 Normalization of GSC markers and GEMPAC score

591 CD44, CD133, EGFR and CD24 were normalized by the sum of CNS markers ATP1B2 and 592 EAAT2 at each time point to investigate changes in relative GSC marker expression. To track the 593 abundance of GBM sEVs in circulation, the GEMPAC score is equal to the sum of normalized all 594 GSC markers.

505	(1) Normalized GSC expression =	GSC marker
292		sum(ATP1B2 + EAAT2)
596	(2) GEMPAC score	
597	= Normalized CD24 + Normalized EGFR + Normalized CD44	
598	+ Normalized CD133	3

599 Statistical analysis

No statistical methods were used to predetermine sample size. All statistical analyses were performed using GraphPad Prism (GraphPad Software v.10.1.2) and values are given as mean \pm sem or sd as indicated. When two groups were compared, significance was determined using an unpaired two-tailed t-test. A log-rank test was used to assess significance in Kaplan– Meier survival analysis. One-way ANOVA, or Two-way ANOVA were used for multiple comparisons, and P values adjusted using Tukey, or Šidák for multiple comparisons where it was appropriate. P value threshold of 0.05 was considered statistically significant.

607 List of Supplementary Materials

- Fig. S1 to S14 for multiple supplementary figures
- Table S1 to S2 for multiple supplementary tables

It is made available under a CC-BY-NC-ND 4.0 International license .

610 Acknowledgments

The authors acknowledge the staff of the NSW Regional Biospecimen Services, University of Newcastle for sourcing the glioblastoma tumor tissue, bloods and clinical data from the Mark Hughes Foundation Biobank and for completing the immunohistochemistry. We also acknowledge the staff from the Histology Facility at the Hunter Medical Research Institute for cutting the tissue blocks and scanning all the slides. We thank the Mark Hughes Foundation for providing funding for the Biobank and for directly funding this work. X.N. acknowledges the China Scholarship Council (CSC) scholarship.

Author contributions: Z.Z., R.J.L., designed and performed experiments, analyzed and interpreted the data, and directed the research. R.L., S.F., P.T., and M.F. were involved in patient sample analysis. Q.Z., was involved in fabrication and chip design. X.N was involved in EV characterization. B.W.D. contributed patient-derived GBM cell lines and supervised cell line study. Z.Z., R.J.L., J.W., S.P., S.R., P.T., and M.T. conceived the study and initiated the research. All authors discussed the results and participated in writing, and revising the manuscript, and approved the submitted version.

625 **Competing interests:** The authors declare no competing interests.

Data and materials availability: The data that support the findings of this study are available
 from the corresponding author upon reasonable request.

It is made available under a CC-BY-NC-ND 4.0 International license .

References

- Cloughesy, T.F., W.K. Cavenee, and P.S. Mischel, *Glioblastoma: From Molecular Pathology to Targeted Treatment*. Annual Review of Pathology: Mechanisms of Disease, 2014. 9(1), 1-25
- 631 2. Saadatpour, L., et al., *Glioblastoma: exosome and microRNA as novel diagnosis*632 *biomarkers.* Cancer Gene Therapy, 2016. 23(12), 415-418
- Tan, A.C., et al., *Management of glioblastoma: State of the art and future directions*. CA:
 A Cancer Journal for Clinicians, 2020. **70**(4), 299-312
- de la Iglesia, N., S.V. Puram, and A. Bonni, *STAT3 regulation of glioblastoma pathogenesis*. Current Molecular Medicine, 2009. 9(5), 580-90
- Hanif, F., et al., *Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment*. Asian Pacific Journal of Cancer Prevention,
 2017. 18(1), 3-9
- 640
 64. Huang, R.Y., et al., *Pitfalls in the neuroimaging of dlioblastoma in the Era of antiangiogenic and immuno/targeted therapy – detecting illusive disease, defining response.* Frontiers in Neurology, 2015. 6, 33
- Müller Bark, J., et al., *Circulating biomarkers in patients with glioblastoma*. British Journal
 of Cancer, 2020. **122**(3), 295-305
- 8. Zikou, A., et al., *Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas.* Contrast Media &
 Molecular Imaging, 2018. 2018, 6828396-6828396
- Sharma, A. and R. Kumar, *Metabolic Imaging of Brain Tumor Recurrence*. AJR. American
 Journal of Roentgenology, 2020. 215(5), 1199-1207
- Shankar, G.M., et al., *Liquid biopsy for brain tumors*. Expert Review of Molecular
 Diagnostics, 2017. **17**(10), 943-947
- Perakis, S. and M.R. Speicher, *Emerging concepts in liquid biopsies*. BMC Medicine, 2017. 15(1), 75
- An, Y., et al., *Recent Advances in Liquid Biopsy of Brain Cancers*. Frontiers in Genetics,
 2021. 12, 720270
- Möller, A. and R.J. Lobb, *The evolving translational potential of small extracellular vesicles in cancer*. Nature Reviews Cancer, 2020. 20(12), 697-709
- Onukwugha, N.E., Y.T. Kang, and S. Nagrath, *Emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology: from target specific isolations to immunomodulation.* Lab Chip, 2022. 22(18), 3314-3339
- 661 15. Gourlay, J., et al., *The emergent role of exosomes in glioma*. Journal of Clinical
 662 Neuroscience, 2017. **35**, 13-23
- 16. Soung, Y., et al., *Exosomes in Cancer Diagnostics*. Cancers, 2017. **9**(12), 8
- 66417.Al-Nedawi, K., et al., Intercellular transfer of the oncogenic receptor EGFRvIII by665microvesicles derived from tumour cells. Nature Cell Biology, 2008. 10(5), 619-24

- García-Romero, N., et al., DNA sequences within glioma-derived extracellular vesicles can
 cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget, 2017. 8(1), 1416-1428
- Osti, D., et al., *Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.* Clinical Cancer Research, 2019. 25(1), 266-276
- Sabbagh, Q., et al., *The von Willebrand factor stamps plasmatic extracellular vesicles from glioblastoma patients*. Scientific Reports, 2021. **11**(1), 22792
- Johnsen, K.B., et al., *What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer.*Biochimica et Biophysica Acta (BBA) Reviews on Cancer, 2019. 1871(1), 109-116
- Kuravi, S.J., et al., Changes in the pattern of plasma extracellular vesicles after severe
 trauma. PLOS ONE, 2017. 12(8), e0183640
- Figueroa, J.M., et al., Detection of wild-type EGFR amplification and EGFRvIII mutation
 in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncology, 2017.
 19(11), 1494-1502
- Gomes, D.E. and K.W. Witwer, *L1CAM-associated extracellular vesicles: A systematic review of nomenclature, sources, separation, and characterization.* Journal of
 Extracellular Biology, 2022. 1(3), e35
- Indira Chandran, V., et al., Ultrasensitive Immunoprofiling of Plasma Extracellular
 Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of
 Glioma. Clinical Cancer Research, 2019. 25(10), 3115-3127
- Mojiri, A., et al., Functional assessment of von Willebrand factor expression by cancer
 cells of non-endothelial origin. Oncotarget, 2017. 8(8), 13015-13029
- Teng, Y.H., R.S. Aquino, and P.W. Park, *Molecular functions of syndecan-1 in disease*.
 Matrix Biology, 2012. **31**(1), 3-16
- 691 28. Li, S., et al., *Targeting* $\beta 2$ subunit of Na(+)/K(+)-ATPase induces glioblastoma cell 692 apoptosis through elevation of intracellular Ca(2). American Journal of Cancer Research, 693 2019. **9**(6), 1293-1308
- Sun, M.Z., et al., Na⁺/K⁺-ATPase β2-subunit (AMOG) expression abrogates invasion of
 glioblastoma-derived brain tumor-initiating cells. Neuro-Oncology, 2013. 15(11), 1518 31
- 697 30. Corbetta, C., et al., Altered function of the glutamate-aspartate transporter GLAST, a
 698 potential therapeutic target in glioblastoma. International Journal of Cancer, 2019.
 699 144(10), 2539-2554
- Suva, M.L. and I. Tirosh, *The Glioma Stem Cell Model in the Era of Single-Cell Genomics*.
 Cancer Cell, 2020. **37**(5), 630-636
- Filbin, M.G., et al., Developmental and oncogenic programs in H3K27M gliomas dissected
 by single-cell RNA-seq. Science, 2018. 360(6386), 331-335
- Tirosh, I., et al., Single-cell RNA-seq supports a developmental hierarchy in human
 oligodendroglioma. Nature, 2016. 539(7628), 309-313

706 707 708	34.	Wuethrich, A., et al., <i>Interfacial nano-mixing in a miniaturised platform enables signal enhancement and in situ detection of cancer biomarkers</i> . Nanoscale, 2018. 10 (23), 10884-10890	
709 710	35.	Robert, S.M. and H. Sontheimer, <i>Glutamate transporters in the biology of malignant gliomas</i> . Cellular and Molecular Life Sciences : CMLS, 2014. 71 (10), 1839-1854	
711 712	36.	Alam, M.A. and P.K. Datta, <i>Epigenetic Regulation of Excitatory Amino Acid Transporter</i> 2 in Neurological Disorders. Frontiers in Pharmacology, 2019. 10 , 483008	
713 714	37.	Shao, H., et al., <i>Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma</i> . Nature Communications, 2015. 6 , 6999	
715 716	38.	Vaillant, B.D., et al., <i>CD44 as a prognostic and predictive marker for GBM</i> . Journal of Clinical Oncology, 2011. 29 (15_suppl), 2049-2049	
717 718	39.	Couturier, C.P., et al., Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nature Communications, 2020. 11 (1), 3406	
719 720 721	40.	Soni, P., et al., <i>CD24 and Nanog expression in Stem Cells in Glioblastoma: Correlation with Response to Chemoradiation and Overall Survival.</i> Asian Pacific Journal of Cancer Prevention, 2017. 18 (8), 2215-2219	
722 723	41.	Senner, V., et al., <i>CD24 promotes invasion of glioma cells in vivo</i> . Journal of Neuropathology & Experimental Neurology, 1999. 58 (8), 795-802	
724 725	42.	Hatanpaa, K.J., et al., <i>Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.</i> Neoplasia, 2010. 12 (9), 675-84	
726 727 728	43.	Brown, D.V., et al., <i>Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.</i> PLOS ONE, 2017. 12 (2), e0172791	
729 730	44.	Si, D., et al., <i>High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas</i> . Cancer Management and Research, 2020. 12 , 769-775	
731 732	45.	Ahmed, S.I., et al., <i>CD133 Expression in Glioblastoma Multiforme: A Literature Review</i> . Cureus, 2018. 10 (10), e3439	
733 734	46.	Liou, G.Y., <i>CD133 as a regulator of cancer metastasis through the cancer stem cells</i> . The International Journal of Biochemistry & Cell Biology, 2019. 106 , 1-7	
735 736	47.	Prager, B.C., et al., <i>Glioblastoma Stem Cells: Driving Resilience through Chaos</i> . Trends in Cancer, 2020. 6 (3), 223-235	
737 738	48.	Bhaduri, A., et al., <i>Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity</i> of Glioblastoma. Cell Stem Cell, 2020. 26 (1), 48-63.e6	
739 740 741	49.	Stringer, B.W., et al., A reference collection of patient-derived cell line and xenograf models of proneural, classical and mesenchymal glioblastoma. Scientific Reports, 2019 9 (1), 4902	
742 743	50.	Lobb, R.J., et al., <i>Optimized exosome isolation protocol for cell culture supernatant and human plasma</i> . Journal of Extracellular Vesicles, 2015. 4 (1), 27031	

- 51. Grabowski, M.M., et al., *Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.* Journal of Neurosurgery, 2014. **121**(5), 1115-23
- Abdoli Shadbad, M., et al., *The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis.* Frontiers in
 Oncology, 2021. 11, 722833
- 53. Behnan, J., G. Finocchiaro, and G. Hanna, *The landscape of the mesenchymal signature in brain tumours*. Brain, 2019. 142(4), 847-866
- 54. De Silva, M.I., B.W. Stringer, and C. Bardy, *Neuronal and tumourigenic boundaries of glioblastoma plasticity*. Trends in Cancer, 2023. 9(3), 223-236
- 55. Kim, Y., et al., *Perspective of mesenchymal transformation in glioblastoma*. Acta
 Neuropathologica Communications, 2021. 9(1), 50
- 56. Halliday, J., et al., *In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift*. Proceedings of
 the National Academy of Sciences, 2014. **111**(14), 5248-5253
- Wang, L., et al., A single-cell atlas of glioblastoma evolution under therapy reveals cell *intrinsic and cell-extrinsic therapeutic targets.* Nature Cancer, 2022. 3(12), 1534-1552
- 58. Genoud, V., et al., *Therapeutic Targeting of Glioblastoma and the Interactions with Its Microenvironment*. Cancers (Basel), 2023. 15(24), 5790
- 59. Lakis, N.S., et al., Stem cell phenotype predicts therapeutic response in glioblastomas with
 MGMT promoter methylation. Acta Neuropathologica Communications, 2022. 10(1), 159
- Fedele, M., et al., Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire
 Multitherapy Resistance in Glioblastoma. International Journal of Molecular Sciences,
 2019. 20(11), 2746
- 767 61. Zaborowski, M.P., et al., *Methods for Systematic Identification of Membrane Proteins for* 768 Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports, 2019. 27(1), 255 769 268 e6
- D'Souza, R.C.J., et al., *Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D Culture.* Cells, 2020. 9(2), 267
- 772 63. Day, B.W., et al., *Glioma surgical aspirate: a viable source of tumor tissue for* 773 *experimental research.* Cancers (Basel), 2013. **5**(2), 357-71
- Visan, K.S., et al., Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles. Journal of Extracellular Vesicles, 2022. 11(9), 12266
- Welsh, J.A., et al., Towards defining reference materials for measuring extracellular
 vesicle refractive index, epitope abundance, size and concentration. Journal of
 Extracellular Vesicles, 2020. 9(1), 1816641
- Wuethrich, A., et al., Single droplet detection of immune checkpoints on a multiplexed
 electrohydrodynamic biosensor. Analyst, 2019. 144(23), 6914-6921

- 783 67. Zhang, Z., et al., *Tracking Drug-Induced Epithelial–Mesenchymal Transition in Breast* 784 *Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay.* Small,
 785 2020. 16(13), 1905614
- Frens, G., Controlled nucleation for the regulation of the particle size in monodisperse
 gold suspensions. Nature Physical Science, 1973. 241(105), 20-22